stella
beta
A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST] — Stella
Recruiting
Back to Primary Malignant Peripheral Nerve Sheath Tumors trials
Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.
Trial locations
(1 site)
United States
University of Minnesota, Minneapolis, Minnesota
View full record on ClinicalTrials.gov